Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

15 clinical studies listed.

Filters:

Thoracic Neoplasms

Tundra lists 15 Thoracic Neoplasms clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07479199

Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors

This study looks at how well a combination of treatments helps reduce pain in people with tumors in the middle and lower back (thoracic and lumbar spine). All participants receive the same treatment, which includes a procedure to stabilize the spine (kyphoplasty), radiofrequency ablation will be with the Osteocool system and radiation therapy. The goal is to see how effective this combined approach is at relieving pain. The purpose of this study is to find out whether combining these three treatments provides better pain relief for patients with thoracic and lumbar spine tumors. This study is for adults who have cancer that has spread to the thoracic or lumbar spine and who report moderate to severe back pain (a pain score of 5 or higher on a 0-10 pain scale).

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-24

1 state

Thoracic Neoplasms
Lumbar Neoplasm
RECRUITING

NCT07159659

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

Lung resection, a critical treatment for various thoracic diseases, including lung cancer, often necessitates prolonged hospitalization due to rare but severe postoperative complications such as chyle leaks, with an occurrence of 0.25%-3%, prolonging chest drainage, and delaying recovery. Therefore, effective postoperative care is essential for optimizing outcomes, reducing complications, and expediting recovery. Recent studies have highlighted the significant potential of medium-chain triglyceride (MCT) diets, owing to their unique absorption pathway and metabolic properties. MCT contains mainly medium-chain fatty acids (MCFA), which is absorbed in the intestine and transported to the liver via the portal system instead of the lymphatic system. This helps to bypass the lymphatic system, thereby reducing the volume of lymph. MCFAs also provide better energy utilization in stressed condition since it does not require carnitine shuttle upon metabolism, which is beneficial to post-operation recovery. Several studies have demonstrated the benefits of MCT diets in managing chyle leaks and supporting gastrointestinal recovery, particularly in conditions that strain the lymphatic system. For instance, short-term MCT-enriched diets have been associated with improved post-operation recovery of gastrointestinal, hepatic and renal functions, reduced total chest drainage volumes, and shorter hospital stay when compared to regular diet groups. Patients with post-operative chyle leak following thoracic surgery are often given an MCT diet to reduce chest drain volume and hence shorten hospital stay. Based on the successful use of MCT diet on patients with chyle leak after lobectomy, it is hypothesized that patients with chylothorax provided with post-operative MCT diet can also shorten hospital stay by decreasing chest drainage. Therefore, a prospective and randomized trial is designed to investigate how post-operative MCT diet in lung resection patients without chylothorax may affect hospital stay and post-operative recovery.

Gender: All

Ages: 18 Years - 80 Years

Updated: 2026-03-20

Thoracic Neoplasms
RECRUITING

NCT05521789

Erector Spinae Block for Thoracic Surgery

The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.

Gender: All

Ages: 18 Years - 90 Years

Updated: 2026-02-25

1 state

Pulmonary Neoplasm
Pulmonary Cancer
Thoracic Diseases
+2
RECRUITING

NCT07242547

Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

This is an open-label, phase II, exploratory and multi-centre clinical trial. 37 Limited stage SCLC patients not eligible for concurrent chemo-radiotherapy will be enroll. Patients will be enrolled in the trial after receiving sequential chemo-radiotherapy, if there is no progression disease, patients will be treated with maintenance Tarlatamab. Patients will receive maintenance with Tarlatamab IV until disease progression unacceptable toxicity, patient or physician decision to discontinue or death. The primary objective is to evaluate the Progression free survival (PFS). Patient accrual is expected to be completed within 2 years. Treatment and follow-up are expected to extend the study duration to a total of 5 years. Patients will be followed for 2 years after enrollment. The study will end once survival follow-up has concluded.

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-04

13 states

Limited-stage Small-cell Lung Cancer
Carcinoma, Small Cell Lung
Respiratory Tract Neoplasms
+1
ACTIVE NOT RECRUITING

NCT06494241

Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study

To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.

Gender: All

Ages: 18 Years - Any

Updated: 2026-01-30

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Respiratory Tract Neoplasms
+7
ACTIVE NOT RECRUITING

NCT06376084

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS .

Gender: All

Ages: 18 Years - Any

Updated: 2026-01-08

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Respiratory Tract Neoplasms
+7
RECRUITING

NCT07205536

Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy

This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2025-12-11

1 state

Myelosuppression
Thoracic Neoplasms
Chemoradiotherapy
RECRUITING

NCT06758700

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2025-12-05

1 state

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Thoracic Neoplasms
Lung Neoplasms
+1
RECRUITING

NCT06917573

PALACE: Cemiplimab Trial According to ctDNA Levels

This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.

Gender: All

Ages: 18 Years - Any

Updated: 2025-11-19

13 states

Non Small Cell Lung Cancer Metastatic
Lung Diseases
Stage IV Non-small Cell Lung Cancer
+3
RECRUITING

NCT06004440

Real World Registry for Use of the Ion Endoluminal System

The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.

Gender: All

Ages: 18 Years - Any

Updated: 2025-11-13

13 states

Lung Cancer
Multiple Pulmonary Nodules
Lung Neoplasms
+6
RECRUITING

NCT06988943

Early Intervention Strategies for Lung Cancer

Low-dose CT (LDCT)can detect and treat lung cancer earlier and more quickly, while expanded screening coverage helps reduce the incidence and mortality of respiratory diseases such as lung cancer. This study aims to conduct a single-arm cluster randomized trial of digitally enabled LDCT in Guangzhou to assess its intervention effectiveness and cost-effectiveness.

Gender: All

Ages: 40 Years - 74 Years

Updated: 2025-05-30

1 state

Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
+4
RECRUITING

NCT06104774

The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery

To explore the effect of a family-centered, eight-week, progressive sit-to-stand Tai Chi exercise on lung function and mental health in patients after thoracoscopic surgery\_

Gender: All

Ages: 18 Years - Any

Updated: 2025-04-24

1 state

Thoracic Neoplasms
NOT YET RECRUITING

NCT06897189

Optimizing Radiation Dose and Utilizing Wearable Devices to Reduce Arrhythmia Risk in Patients Undergoing Thoracic Radiotherapy: A Prospective Cohort Study

This prospective observational cohort study aims to assess the risk of radiation-induced cardiotoxicity in patients undergoing thoracic radiotherapy by integrating real-time arrhythmia monitoring using wearable cardiac rehabilitation (wearable CR) devices and AI-based cardiac substructure segmentation. The study will analyze radiation dose exposure to key cardiac structures, including the sinoatrial node (SAN) and pulmonary veins (PV), to identify risk factors for atrial fibrillation (AF) and other arrhythmias. Patients will receive wearable CR monitoring at 3, 12, and 24 months post-radiotherapy, with cardiology follow-up and intervention based on standard clinical guidelines. The study will recruit 111 patients over three years, with a two-year follow-up after radiotherapy. The primary endpoint is the incidence of grade 3+ AF within 2 years, with secondary outcomes including any-grade arrhythmia rates, arrhythmia burden, and survival analysis. By establishing a prospective thoracic radiotherapy patient cohort, this study aims to identify dose-related risk factors, improve early detection and management of radiation-induced arrhythmias, and provide evidence-based strategies to enhance treatment safety and efficacy.

Gender: All

Ages: 20 Years - Any

Updated: 2025-04-18

Cardiotoxicity
Thoracic Radiotherapy
Wearable Electronic Devices
+2
ACTIVE NOT RECRUITING

NCT04776447

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment (Atezolizumab + Induction chemotherapy (CT) + CT-Radiotherapy) in terms of the Progression Free Survival at 12 months

Gender: All

Ages: 18 Years - 75 Years

Updated: 2025-04-09

5 states

Lung Diseases
Carcinoma, Non-Small-Cell Lung
Stage IIIA Non-small Cell Lung Cancer
+4
RECRUITING

NCT06177925

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin/Cisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2023-12-20

Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
+7